Preparation & Measurement Guide

Tirzepatide 20mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 20mg vial.

Research use only Educational comparator summary. This research material is not an approved drug product.
Vial Size Tirzepatide 20mg
Preparation 2mL bacteriostatic water
Concentration 10mg/mL after preparation
Documented Convention 2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 20mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

20mg / 2mL = 10mg/mL
1 U-100 unit = 0.01mL = 100mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2.5mg once weekly 0.25mL / 25 units
Weeks 5-8 5mg once weekly 0.5mL / 50 units
Weeks 9-12 7.5mg once weekly 0.75mL / 75 units
Weeks 13-16 10mg once weekly 1mL / 100 units
Weeks 17-20 12.5mg once weekly 1.25mL / 125 units*
Weeks 21+ 15mg once weekly 1.5mL / 150 units*

Vial estimate: One 20mg vial contains approximately 8 administrations at the first listed amount or 1 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Tirzepatide 20mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

  1. FDA Zepbound prescribing information
  2. SURMOUNT-1 tirzepatide obesity trial
  3. SURMOUNT-3 tirzepatide clinical trial

Research Materials

Review Tirzepatide 20mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: Tirzepatide 20mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.